Dr. Shahram Hejazi is a life science investor and entrepreneur with general management experience in both early-stage ventures and large global companies. As a Partner with BioAdvance, he is responsible for investments in research tools, devices, diagnostics and health IT. He is a Board Member for Halo Labs Inc., WellTrackOne Inc., Talex Medical LLC, Bainbridge Health LLC, Keriton Inc., Enzium Inc., and HealthQX LLC (acquired by McKesson). He is a board observer for WellSheet Inc., Oncora Medical Inc. and Cohero Health Inc. He is also the Chairman of Pediatric Device Consortium fund at CHOP. Shahram is the 2014 James Wei Visiting Professor of Entrepreneurship at Princeton University where he is currently a part-time faculty.
Previously, Dr. Hejazi was the President of Kodak’s life science division (now called Carestream Molecular Imaging), where he had global responsibility for R&D, manufacturing, operations, sales, marketing and service. While holding this position, Dr. Hejazi led the system business to successful double-digit annual growth and directed the launch of a new imaging agent business.
Before Kodak, he was the CEO of Zargis Medical Corporation (an early stage medical device company that spun-off from Siemens), where he led the company’s efforts in areas ranging from raising capital and technology development to completion of several clinical trials, FDA approval and product launch- the company was later sold to 3M. Prior to Zargis, Dr. Hejazi was the Head of the Strategic Business Development group at Siemens, responsible for identifying growth/investment opportunities and new business development in life sciences and health IT. At Siemens, he was instrumental in establishing the Siemens corporate medical venture unit, as well as the acquisition of Shared Medical Systems.
Earlier in his career, Dr. Hejazi held R&D management positions within the diagnostic imaging and nanotechnology fields at Kodak and IBM, respectively. In addition to his Board responsibilities at BioAdvance, Shahram is also the Chairman of the advisory board of Integral Molecular Inc. His past Board responsibilities includes FDA Industry Advisory Panel Member for Molecular and Clinical Genetic Devices, Fox Chase Cancer Center, Bioscan Inc., Alpha Innotech Corp. Shahram is the author of over 10 scientific publications and has a PhD in electrical engineering with emphasis in biophysics (SUNY at Buffalo) and an executive business education (Stanford University).